NEW YORK (
was the biggest gainer among small-caps Thursday after the biotech company won approval for its first drug Horizant used to treat moderate-to-severe restless leg syndrome. The stock was up 66% at $10.64 on volumes of more than 17 million shares.
jumped 21% to $11.28 after an experimental breast cancer drug that it is developing with
was found to be more successful than the standard treatment in a mid-stage study.
Retail stocks were buzzing after stronger-than-expected same-store sales data.
Pier 1 Imports
saw its shares climb 9% to $11.52 after it reported better-than-expected results. Sales rose 7.7% to $426.6 million, beating the analysts' average estimate of $425.6 million. Sales at stores open at least a year rose 8.9%.
was up 6.6% to $1.13 after it posted a narrower-than-expected loss and its sales stabilized. The company said it may narrow its losses significantly in fiscal 2012, and forecasted stronger revenue than analysts expected.
shares were climbing 4.5% to $20.23. The company announced the pricing of the offering of 19,800,000 common shares by certain stockholders at $19 a share, reflecting an upsize from the previously announced offering of 16.5 million shares.
rose rising 5.8% to $14.09.
Stocks of semiconductor companies were climbing after
said earlier this week it will acquire
for $6.5 billion.
Rare Element Resources
Avalon Rare Metals
were soaring 10.7% and 4.9%, respectively. A bill was introduced Wednesday that would benefit U.S. rare earth miners, according to a
release from the U.S. Magnetic Materials Association.
--Written by Shanthi Bharatwaj in New York
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
Disclosure: TheStreet's editorial policy prohibits staff editors and reporters from holding positions in any individual stocks.